RP — Replicel Life Sciences Share Price
0.000.00%
Last trade - 00:00- CA$0.74m
- CA$1.19m
- CA$0.35m
- 12
- 63
- 16
- 20
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.08 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -190.01% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | n/a | n/a | 23.91% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
RepliCel Life Sciences Inc. is a regenerative medicine company engaged in developing autologous cell therapies to treat conditions linked to a deficit of healthy cells required for normal healing and function. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product consists of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. The Company has also developed a proprietary injection device (DermaPrecise) and related consumables, which is expected to improve the administration of its cell therapy products and certain other injectables. DermaPrecise is a dermal injector and motorized injection device with programmable depth and volume, a built-in Peltier element for pre-injection numbing of the skin and interchangeable needle head configurations.
Directors
- David Hall NEC
- R. Lee Buckler PRE
- Simon Ma CFO (55)
- Rolf Hoffmann OTH (58)
- Gary Boddington DRC
- Peter Lewis IND
- Peter Lowry IND
- Andrew Schutte IND
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- June 22nd, 2011
- Public Since
- September 29th, 2012
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 73,577,807
- Address
- 570 Granville St Suite 900, VANCOUVER, V6C 3P1
- Web
- https://www.replicel.com/
- Phone
- +1 6042488693
- Auditors
- Mao & Ying LLP
Upcoming Events for RP
Q1 2025 Replicel Life Sciences Inc Earnings Release
Q2 2025 Replicel Life Sciences Inc Earnings Release
Similar to RP
Hemostemix
TSX Venture Exchange
Innovotech
TSX Venture Exchange
KDA
TSX Venture Exchange
Marvel Biosciences
TSX Venture Exchange
Medicure
TSX Venture Exchange
FAQ
What is the Replicel Life Sciences share price?
As of Today at 21:54 UTC, shares in Replicel Life Sciences are trading at CA$0.01. This share price information is delayed by 15 minutes.
How has the Replicel Life Sciences share price performed this year?
Shares in Replicel Life Sciences last closed at CA$0.01 and the price had moved by -72.73% over the past 365 days. In terms of relative price strength the Replicel Life Sciences share price has underperformed the Toronto Stock Exchange 300 Composite Index by -76.85% over the past year.
What are the analyst and broker recommendations for Replicel Life Sciences?
The overall consensus recommendation for Replicel Life Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Replicel Life Sciences dividend yield?
Replicel Life Sciences does not currently pay a dividend.
Does Replicel Life Sciences pay a dividend?
Replicel Life Sciences does not currently pay a dividend.
When does Replicel Life Sciences next pay dividends?
Replicel Life Sciences does not currently pay a dividend.
How do I buy Replicel Life Sciences shares?
To buy shares in Replicel Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Replicel Life Sciences?
As of the previous close price of CA$0.01, shares in Replicel Life Sciences had a market capitalisation of CA$0.74m.
Where are Replicel Life Sciences shares listed?
Here are the trading details for Replicel Life Sciences:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: RP
What kind of share is Replicel Life Sciences?
Based on an overall assessment of its quality, value and momentum Replicel Life Sciences is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Replicel Life Sciences share price forecast for 2025?
The analyst consensus target price for shares in Replicel Life Sciences is CA$2.15. That is 21400% above the last closing price of CA$0.01.
Analysts covering Replicel Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Replicel Life Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Replicel Life Sciences. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -75.25%.
As of the last closing price of CA$0.01, shares in Replicel Life Sciences were trading -90.02% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Replicel Life Sciences PE Ratio?
The Replicel Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Replicel Life Sciences?
Replicel Life Sciences' management team is headed by:
- David Hall - NEC
- R. Lee Buckler - PRE
- Simon Ma - CFO
- Rolf Hoffmann - OTH
- Gary Boddington - DRC
- Peter Lewis - IND
- Peter Lowry - IND
- Andrew Schutte - IND